New 45-Minute Sound Therapy Sessions Following Ketamine Treatment Offer Deeper Relaxation, Emotional Release, and Enhanced Healing
Read More
Pre-eminent Peer-Reviewed Cybercrime Conference Examines Physical Impact of Cybercrime Driven by AI Innovations -- Underwritten by a Newly Wealthy Criminal Culture
Read More- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis -
- Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors -